{"type":"trials","record":{"id":42267,"source_id":"clinicaltrials-gov","external_id":"NCT05342857","title":"Maximum Treatment Interval With Aflibercept T&E","brief_summary":"To evaluate the duration of effectiveness of anti-VEGF (Aflibercept) by analyzing the percentage of patients whose maximum treatment interval is extended to 16 weeks and beyond in 24 months and their long-term remission.","overall_status":"Unknown","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Shin Kong Wu Ho-Su Memorial Hospital","enrollment":100,"countries":["Taiwan"],"start_date":"2022-01-01","completion_date":"2025-04-01","last_update_date":"2022-04-25","source_url":"https://clinicaltrials.gov/study/NCT05342857","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":null,"comparator":null,"organization":"Shin Kong Wu Ho-Su Memorial Hospital","interventions":["Aflibercept Injection [Eylea]"],"registry_source":"ClinicalTrials.gov","outcome_measures":["The percentage of patients whose maximum treatment interval is extended to 24 months — 2 years","Find the prediction factors associated with extension to 16 weeks and beyond by univariate and multivariate analysis —…","Find the prediction factors associated with occurrence of disease activity by univariate and multivariate analysis — 2…","The percentage of patients whose maximum treatment interval is extended to 16 weeks and beyond in 24 months in PCV and…","Mean change in BCVA from baseline to month 24 — 2 years","Mean change in central subfield thickness from baseline to month 24 — 2 years","Proportion of patients who gain ≧15 ETDRS letters from baseline to month 24 — 2 years","Mean number of injections in each group from baseline to month 24 — 2 years","Mean treatment interval from baseline to month 24 — 2 years"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Aflibercept Injection [Eylea]"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05342857","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-01-01 to 2025-04-01","comparator":null,"confidence":"structured-source","population":"ALL","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.944Z","intervention":["Aflibercept Injection [Eylea]"],"participants":100,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The percentage of patients whose maximum treatment interval is extended to 24 months — 2 years","Find the prediction factors associated with extension to 16 weeks and beyond by univariate and multivariate analysis —…","Find the prediction factors associated with occurrence of disease activity by univariate and multivariate analysis — 2…","The percentage of patients whose maximum treatment interval is extended to 16 weeks and beyond in 24 months in PCV and…","Mean change in BCVA from baseline to month 24 — 2 years","Mean change in central subfield thickness from baseline to month 24 — 2 years","Proportion of patients who gain ≧15 ETDRS letters from baseline to month 24 — 2 years","Mean number of injections in each group from baseline to month 24 — 2 years","Mean treatment interval from baseline to month 24 — 2 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42267","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}